NXT 211

Drug Profile

NXT 211

Alternative Names: Anti-ferritin antibody-Y90; NXT211; Radiolabelled anti-isoferritin antibody

Latest Information Update: 29 Jun 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NEXTherapeutics
  • Class Antibodies; Antibody diagnostics; Antineoplastics; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters; Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer; Hodgkin's disease

Most Recent Events

  • 29 Jun 2011 No development reported - Clinical-Phase-Unknown for Hodgkin's disease in USA (unspecified route)
  • 29 Jun 2011 No development reported - Preclinical for Cancer in USA (unspecified route)
  • 17 Feb 2004 Preclinical trials in Cancer (diagnosis) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top